Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics.
Large-scale, renewable supplies of chemical constituents derived from marine invertebrates have limited development of potential new natural product drugs. This paper describes the development of two in-sea aquaculture systems designed and engineered for production of large quantities of biomass for two species of marine invertebrates desired for their natural product chemical constituents. The two invertebrates and their products were: (1) the cosmopolitan, arborescent bryozoan Bugula neritina (Phylum Bryozoa) for its anticancer chemical constituent bryostatin 1; and (2) Ecteinascidia turbinate (Phylum Tunicata) the source of anticancer ecteinascidin 743. For the third invertebrate Phylum Porifera, and its representative sponge Acanthella cavernosa (desired for its anti-parasitic and anti-infective kalihinols) in-sea systems were not developed in favor of controlled environment tank aquaculture systems. For the bryozoan and tunicate, projected economics for commercial-scale in-sea production proved cost effective. This was in contrast to the controlled environment sponge culture tank system, which did not prove to be economical due to inherent slow growth and low natural product yields of the sponge in culture. A non-destructive method for "milking" natural product chemicals from sponges was tested and is described.
Mendola
Dominick
D
CalBioMarine Technologies, Inc., 1001 Capri Road, Encinitas, CA 92024, USA. cbmt@pacbell.net
D000818:Animals; D000890:Anti-Infective Agents / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism; D000970:Antineoplastic Agents / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism; D017756:Aquaculture / Q000191:economics* / Q000295:instrumentation* / Q000379:methods; D001685:Biological Factors / Q000191:economics* / Q000302:isolation & purification / Q000378:metabolism*; D019149:Bioreactors / Q000191:economics; D054713:Bryostatins; D002013:Bryozoa / Q000254:growth & development / Q000378:metabolism; D004149:Dioxoles / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism; D004780:Environment, Controlled; D007185:Incubators; D007448:Invertebrates / Q000254:growth & development / Q000378:metabolism*; D007546:Isoquinolines / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism; D007783:Lactones / Q000191:economics / Q000302:isolation & purification / Q000378:metabolism; D018942:Macrolides; D008386:Marine Biology / Q000191:economics* / Q000295:instrumentation* / Q000379:methods; D011161:Porifera / Q000254:growth & development / Q000378:metabolism; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin; D014481:United States; D014561:Urochordata / Q000254:growth & development / Q000378:metabolism
D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D001685:Biological Factors; D054713:Bryostatins; D004149:Dioxoles; D007546:Isoquinolines; D007783:Lactones; D018942:Macrolides; D044005:Tetrahydroisoquinolines; C046785:bryostatin 1; D000077606:Trabectedin